|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0002844,
umls-concept:C0013216,
umls-concept:C0030705,
umls-concept:C0035820,
umls-concept:C0040223,
umls-concept:C0085862,
umls-concept:C0138741,
umls-concept:C0220901,
umls-concept:C0332293,
umls-concept:C0439830,
umls-concept:C1705764
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2007-10-1
|
|
pubmed:abstractText |
To investigate whether the prostate-specific antigen doubling time (PSADT) and velocity (PSAV) at the emergence of androgen-independent prostate cancer (AIPC) provide independent prognostic information.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1527-9995
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
70
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
527-31
|
|
pubmed:meshHeading |
pubmed-meshheading:17905110-Adenocarcinoma,
pubmed-meshheading:17905110-Adult,
pubmed-meshheading:17905110-Aged,
pubmed-meshheading:17905110-Androgen Antagonists,
pubmed-meshheading:17905110-Androgens,
pubmed-meshheading:17905110-Antineoplastic Agents, Hormonal,
pubmed-meshheading:17905110-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:17905110-Drug Resistance, Neoplasm,
pubmed-meshheading:17905110-Humans,
pubmed-meshheading:17905110-Male,
pubmed-meshheading:17905110-Middle Aged,
pubmed-meshheading:17905110-Neoplasms, Hormone-Dependent,
pubmed-meshheading:17905110-Paclitaxel,
pubmed-meshheading:17905110-Prognosis,
pubmed-meshheading:17905110-Proportional Hazards Models,
pubmed-meshheading:17905110-Prostate-Specific Antigen,
pubmed-meshheading:17905110-Prostatic Neoplasms,
pubmed-meshheading:17905110-Retrospective Studies,
pubmed-meshheading:17905110-Salvage Therapy,
pubmed-meshheading:17905110-Survival Analysis,
pubmed-meshheading:17905110-Taxoids,
pubmed-meshheading:17905110-Time Factors
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy.
|
|
pubmed:affiliation |
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Evaluation Studies
|
